न्यूरोफिज़ियोलॉजी अनुसंधान


Brain stimulation by Neuroprotective therapy both for acute ischemic stroke and ALS

Koji Abe

Neuroprotection is an important deal for brain stimulation, and essential for potential therapy not only in acute stage of stroke but also in chronic progressive neurodegenerative diseases such as ALS. Edaravone is a free radical scavenger, which is especially useful in thrombolytic therapy with tissue plasminogen activator (TPA) for reducing hemorrhagic transformation. An intensive Edaravone therapy for 3 days now showed a favorite recovery in 3 European countries. Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neurodegenerative disease caused by selective death of motor neurons. Although the underlying mechanism of ALS has not yet been fully clarified, several reports have implicated the involvement of oxidative stress under selective death of motor neurons in both ALS patients and animal models A recent clinical trial with edaravone showed a positive effect for ALS with delaying the clinical score (ALSFRS- R) during the course of examination (24 weeks). Of particular was that this clinical benefit of edaravone was shown as an add-on therapy after anti-glutamatergic riluzole. Edaravone is approved for ALS on 2015 in Japan, 2016 in Korea, and 2017 in USA, and currently in consideration for EU countries.